PD+: A comprehensive, user-friendly mobile application for clinicians treating Parkinson’s Disease
Objective: We developed a mobile application that converts dopaminergic medication dosages and calculates total Levodopa (L-dopa) equivalent daily dose (LEDD) in a Parkinson’s Disease (PD)…Delayed Osmotic Demyelination Syndrome- An Evolving Spectrum
Objective: To report a case of osmotic demyelination syndrome (ODS) with continuing clinical and radiological worsening beyond its previously established temporal course. Background: ODS is…Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson’s Disease Patients with Motor Fluctuations
Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg on the pharmacokinetics (PK) of levodopa (LD) in different LD/carbidopa (LD/CD)…Descriptive case studies of patients in their fifth consecutive year of treatment with ND0612
Objective: To describe the long-term experience of three individual patients receiving subcutaneous (SC) levodopa/carbidopa infusion with ND0612 in an open-label clinical safety study. Background: ND0612…Gait analysis using Wearable Sensors: different gait metrics can differentiate Parkinson’s Disease Patients from Healthy Controls and Parkinson’s Disease patients in different medication status
Objective: To identify which gait metrics better distinguish PD-OFF from PD Best-ON and PD from HC, using a dimensionality-reduction method Background: Objective gait analysis using…Clinical Characteristics of patients with Parkinson’s disease showing normal values on SBR in the DAT SPECT
Objective: The aim of this study was to clarify what the ‘normal’ values of the specific binding ratio (SBR), a measure of striatal radiotracer uptake…Quality of life and patient reported outcomes with subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 BeyoND study
Objective: To review quality of life and other patient reported outcomes data from the ND0612 BeyoND study. Background: ND0612 is in development as a continuous,…Can we add whey protein supplementation in patients with Parkinson’s disease without interfering with levodopa response?
Objective: The main endpoint of the study was to evaluate if a daily intake of whey protein-based dietary supplement causes a worse response to levodopa…Response of freezing, posture and voice to increasing levodopa doses in Parkinson’s disease
Objective: To analyze the resistance to high levodopa doses of FoG, posture, speech, and gait features in PD patients during a daily-ON therapeutic condition. Background:…Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Data from patients who continued past one year in the BeyoND study
Objective: To report long-term safety and tolerability data from the ongoing BeyoND study (NCT02726386) for patients who continued treatment past the one-year primary endpoint. Background:…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 62
- Next Page »